Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 09 Jan 2018 Planned number of patients changed from 25 to 35.
- 09 Jan 2018 Planned End Date changed from 31 Jan 2019 to 31 Jul 2019.
- 09 Jan 2018 Planned primary completion date changed from 31 Mar 2018 to 30 Sep 2018.